First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024
Phase 2 interim data for both mRNA therapeutic programs on track for first half of 2025
https://www.businesswire.com/news/home/20250106386740/en/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.